Stock Events

Orgenesis 

$1.2
21
-$0.3-20% Today

Statistics

Day High
1.55
Day Low
1.12
52W High
10.8
52W Low
1.12
Volume
59,704
Avg. Volume
37,155
Mkt Cap
31.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

8
NOV
Earnings
 

Earnings

8NovExpected
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.29
-0.13
0.02
0.18
Expected EPS
0.17
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORGS. It's not an investment recommendation.
Alphabet
78260
GOOGL
Apple
68069
AAPL
Microsoft
63506
MSFT
Amazon
59244
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is involved in gene editing, a direct competitor to Orgenesis's cell and gene therapy technologies.
Bluebird bio
BLUE
Mkt Cap108.22M
bluebird bio specializes in gene therapies for severe genetic diseases and cancer, overlapping with Orgenesis's focus areas.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy, competing in the same space as Orgenesis.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is a leading gene editing company using CRISPR/Cas9 technology, competing in the gene therapy sector.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the CRISPR gene editing space, making it a direct competitor to Orgenesis's gene therapy efforts.
Pfizer
PFE
Mkt Cap164.39B
Pfizer has a growing portfolio in gene therapy, making it a competitor to Orgenesis, especially in commercialization and development.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and has ventured into gene therapy, competing with Orgenesis.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space, particularly in cancer, which is a focus for Orgenesis.
Adverum Biotechnologies
ADVM
Mkt Cap144.36M
Adverum Biotechnologies is developing gene therapy treatments for ocular and rare diseases, competing in the gene therapy market.

About

Health Technology
Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Show more...
CEO
Vered Caplan
Employees
146
Country
US
ISIN
US68619K2042

Listings

XNAS
US
ORGS
F
DE
45O0.F